Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy
- 28 February 2006
- journal article
- review article
- Published by Elsevier BV in European Journal of Surgical Oncology
- Vol. 32 (1), 55-64
- https://doi.org/10.1016/j.ejso.2005.09.010
Abstract
No abstract availableKeywords
This publication has 92 references indexed in Scilit:
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Use of proteomic analysis to monitor responses to biological therapiesExpert Opinion on Biological Therapy, 2004
- p53, Deleted in Colorectal Cancer Gene, and Thymidylate Synthase as Predictors of Histopathologic Response and Survival in Low, Locally Advanced Rectal Cancer Treated With Preoperative Adjuvant TherapyDiseases of the Colon & Rectum, 2003
- Response to preoperative chemoradiation increases the use of sphincter‐preserving surgery in patients with locally advanced low rectal carcinomaCancer, 2003
- DNA microarray technology in cancer researchEuropean Journal of Surgical Oncology, 2001
- p53, BCL-2, and Ki-67 Expression According to Tumor Response After Concurrent Chemoradiotherapy for Advanced Rectal CancerAnnals of Surgical Oncology, 2001
- The Hallmarks of CancerCell, 2000
- Disruption of p53 in human cancer cells alters the responses to therapeutic agentsJCI Insight, 1999
- p53 Status and the Efficacy of Cancer Therapy in VivoScience, 1994
- Prolongation of the Disease-Free Interval in Surgically Treated Rectal CarcinomaNew England Journal of Medicine, 1985